Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Actelion Ltd. (OTC: ALIOF).

Full DD Report for ALIOF

Recent News from (OTC: ALIOF)

Books will close today today November 9, 2017.
Books will close today today November 9, 2017.
Source: OTC Markets
Date: November, 09 2017 00:00
Books will close today today November 7, 2017.
Books will close today today November 7, 2017.
Source: OTC Markets
Date: November, 07 2017 00:00
Books will close today today November 6, 2017.
Books will close today today November 6, 2017.
Source: OTC Markets
Date: November, 06 2017 00:00
ALIOY Books closed today, June 14, 2017
ALIOY Books closed today, June 14, 2017
Source: OTC Markets
Date: June, 14 2017 00:00
Cross-Border M&A Between U.S. And European Firms At 10-Year High
By Pamela Barbaglia Some $171.8 billion of cross-border merger & acquisition deals between U.S. and European companies have been announced so far in 2017, the highest figure at this stage of the year for a decade as companies on both sides of the Atlantic hunt for deals to offset slu...
Source: SeekingAlpha
Date: May, 25 2017 00:49
Actelion (ALIOF) Investor Presentation - Slideshow
The following slide deck was published by Actelion Ltd. in conjunction with this Read more ...
Source: SeekingAlpha
Date: May, 23 2017 13:51
Johnson & Johnson Lays Out Its Battle Plan
Johnson & Johnson's (JNJ) pharma engine is faltering, and it needs more fuel. But it is unclear whether its list of potential new blockbusters will give it the boost it needs. Among the 11 projects highlighted - plus ponesimod, which it will gain when it closes the acquisition of Actelio...
Source: SeekingAlpha
Date: May, 19 2017 14:47
Snippet Roundup: Tesaro's Parp Pricing Stumble And Asco Sneak Peek
Welcome to your weekly roundup of EP Vantage's snippets - short takes on smaller news items. This week, April 17 to 21, 2017, we had thoughts on the following: Atara (ATRA) touts T-cell promise in multiple sclerosis; Tesaro (TSRO) stumbles on Zejula pricing strategy; Verily plays long game w...
Source: SeekingAlpha
Date: April, 21 2017 15:32
Johnson & Johnson: No Surprises Here
Johnson & Johnson (JNJ) is down around 3% after the healthcare products company reported disappointing Q117 results . The recent rally and the meager organic growth supports my previous research that the stock was vastly overvalued. Despite this warning, JNJ rallied to new highs rec...
Source: SeekingAlpha
Date: April, 18 2017 15:55
Premarket analyst action - healthcare
Cytokinetics (NASDAQ: CYTK ) initiated with Buy rating and $25 (117% upside) price target by Roth Capital. More news on: Cytokinetics, Incorporated, Bellicum Pharmaceuticals, Impax Laboratories, Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: March, 08 2017 08:18

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-04-24N/A278.50N/AN/A0
2018-04-23N/A278.50N/AN/A0
2018-04-22N/A278.50N/AN/A0
2018-04-21N/A278.50N/AN/A0
2018-04-20N/A278.50N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2017-09-187021,10263.7024Short
2017-08-31671,1925.6208Cover
2017-08-3026028192.5267Short
2017-08-142020100.0000Short
2017-07-267354,68015.7051Cover

* Short Mode

Short Analysis provided by Squeeze Report.


About Actelion Ltd. (OTC: ALIOF)

Logo for Actelion Ltd. (OTC: ALIOF)

Actelion Pharmaceuticals Ltd is a biopharmaceutical company headquartered in Allschwil/Basel, Switzerland, that focuses on the discovery, development and commercialization of innovative treatments to serve high unmet medical needs.

 

 

 

Current Management

  • Jean Paul Clozel / CEO
    • JeanPaul Clozel d.o.b. April is a cardiologist educated in France, with further training in pharmacology and physiology at the University of Montreal, Canada, and the University of California, San Francisco. After eleven years as a clinician, he decided to move to applied research. During his years at F. HoffmannLa Roche Ltd, he was responsible for the selection of the first Tchannel blocker. He also participated in the characterization of renin inhibitors as well as several endothelin receptor antagonists such as bosentan and clazosentan. Overall, the group he was heading discovered seven compounds that entered clinical trials. During his yearcareer in cardiology, he has published widely in peerreviewed medical and scientific journals. At the same time, his passion has remained unchanged: being involved as closely as possible in bringing innovative medicine to his patients. He has developed various, novel experimental models allowing the differentiation of these drugs, work honored with the HoffmannLa Roche Research Prize. In he was nominated professor at the Coll ge de France in Paris, France Chair of Technical Innovation . At the end of , JeanPaul founded Actelion, together with his wife, Martine, and work colleagues and friends Walter Fischli and Thomas Widmann. First mainly focusing on Research and Development, he became CEO of the company to bring Actelion to the public in April .
  • Konrad A. Wirz / CFO
  • Andrew Oakley / CFO
  • Andre C. Muller / CFO
    • Andre C. Muller is a French citizen and holds an MBA from the Business School EM Lyon. Andre joins Actelion from Pierre Fabre SA, an international pharmaceutical and cosmetic group where he held various position from until , most recently as Chief Financial Officer. Andre joined Actelion in September , as Executive VicePresident, Chief Financial Officer and a member of the Actelion Executive Committee.
  • Otto Schwarz / EVP, COO
    • Otto Schwarz is an Austrian citizen with a PhD in pharmaceutical chemistry from Vienna University. Prior to joining Actelion, he was Executive VicePresident Commercial Operations at Nycomed former Altana Pharma AG where he oversaw commercial operations in more than countries. Previously, Otto worked for almost years at Eli Lilly and ScheringPlough providing him with the opportunity to either lead or participate in major drug launches and major strategic alliances with third parties. Otto joined Actelion in and is currently Executive VicePresident, Chief Operating Officer and a member of the Actelion Executive Committee.
  • Tom Monroe / VP, Fin.
  • Mareike Borchert / IR Manager

Current Share Structure

  • Market Cap: $36,235,217,250 - 03/15/2018
  • Issue and Outstanding: 130,108,500 - 03/31/2011

 



Daily Technical Chart for (OTC: ALIOF)

Daily Technical Chart for (OTC: ALIOF)


Stay tuned for daily updates and more on (OTC: ALIOF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ALIOF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALIOF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of ALIOF and does not buy, sell, or trade any shares of ALIOF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/

 

 

Release this Report to Investors

Via Email

Via Text

Important

If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us